India’s pharmaceutical sector raised USD 294 million (approximately INR 2,450 crore) across 18 deals in July 2025, according to data from Tracxn. This marks a sharp rebound in investor sentiment with funding jumping 2,356.8 percent over June 2025’s USD 12 million and up 574.1 percent compared to July 2024. It also represents a 20 percent rise from May 2025, which saw USD 245.8 million in inflows.

Late-stage funding dominated, accounting for 92.3 percent of the total capital raised, while seed-stage deals comprised 4.2 percent and early-stage rounds 3.5 percent.

Meril led the pack with a USD 200 million (approximately INR 1,666 crore) fundraise—the month’s largest deal. Other major transactions included MedGenome (USD 47.5 million), Truemeds (USD 20 million), SAI Parenterals (USD 5.8 million), and USD 4 million each for Pristyn Care and Luma Fertility. Biopeak raised USD 3.5 million.

Peak XV Partners emerged as the most active venture capital firm, backing Truemeds, Pristyn Care, and Luma Fertility. Samarah Capital participated in SAI Parenterals’ round, while Gujarat Venture Finance invested in Genexis Biotech.

The report highlights three major trends: a sharp recovery in funding activity, late-stage dominance versus June’s early-stage focus, and a funding surge largely led by high-value transactions like Meril’s.